MARKET TALK: BarCap Upgrades AstraZeneca To Overweight
11th Jun 2010 07:28
0628 GMT [Dow Jones] Barclays Capital upgrades AstraZeneca (AZN) to overweight from equalweight and lifts its target price to 3400p from 3300p. "Due diligence around the Crestor US patent litigation leads us to consider the risks sufficiently tolerable for a more positive view of the stock." It says
Read morePRESS RELEASE: Ron Laufer named Senior Managing Director of MedImmune Ventures
10th Jun 2010 13:00
GAITHERSBURG, Md., June 10 /PRNewswire/ -- MedImmune announced today that Ron Laufer, M.D., has been appointed Senior Managing Director of MedImmune Ventures, the company's venture capital arm. Laufer's appointment will strengthen MedImmune's long-term commitment to supporting scientific innovation
Read moreAstraZeneca Buys Back 0.3M Shares At 2912P Each
9th Jun 2010 08:16
LONDON (Dow Jones)--AstraZeneca PLC (AZN.LN) said Wednesday it purchased for cancellation 330,000 ordinary shares at a price of 2912 pence per share. -Shares at 0715 GMT up 6.5 pence, or 0.22%, at 2927.5 pence. -By Iain Packham, Dow Jones Newswires; 44-20-7842-9269; [email protected]
Read moreIN THE PIPELINE: Micromet Grabs Immune System In Cancer Fight
8th Jun 2010 16:00
By Thomas Gryta Of DOW JONES NEWSWIRES NEW YORK (Dow Jones)--Micromet Inc. (MITI) is developing drugs that use an aggressive approach to using the body's own defenses in fighting cancer. Unlike Dendreon Corp.'s (DNDN) recently approved Provenge, which works like a vaccine to stimulate an
Read moreAstraZeneca Buys Back 0.15M Shares At 2910P Per Share
8th Jun 2010 08:28
LONDON (Dow Jones)--AstraZeneca PLC (AZN.LN) said Tuesday it purchased for cancellation 150,000 ordinary shares at a price of 2910 pence per share. -Shares at 0727 GMT down 12.5 pence, or 0.43%, at 2913.5 pence. -By Iain Packham, Dow Jones Newswires; 44-20-7842-9269; [email protected]
Read moreLondon close: Footsie ends up
18th May 2010 16:42
Footsie finished with good gains but edged down from earlier highs after a poor start on Wall Street. Man Group was the best performer on reflection of yesterday's deal to buy GLG for $1.6bn. Inter-dealer broker ICAP was also in demand, ahead of its full year results tomorrow, while mezzanine finan
Read moreLondon midday: Decent morning for Footsie
18th May 2010 12:10
Footsie has made decent progress this morning helped by gains for utilities and the non-bank and insurance bits of the finance sector. Man Group is the best performer on reflection of yesterday's deal to buy GLG for $1.6bn. Inter-dealer broker ICAP is also in demand, while mezzanine finance lende
Read moreLondon open: Bright start for Footsie
18th May 2010 09:02
Footsie has made good progress in early dealing with miners rallying and some decent results this morning. Mobile giant Vodafone expects to see revenues in its core business grow again in the current year after recent declines with a promise of dividend growth of at least 7% for the next three year
Read moreLondon pre-open: Shares to move higher
18th May 2010 07:40
Footsie is expected to move ahead following an improvement on Wall Street following the close here yesterday Mobile giant Vodafone expects to see revenues in its core business grow again in the current year after recent declines with a promise of dividend growth of at least 7% for the next three ye
Read moreAstraZeneca grants Teva generic Crohn's drug license
18th May 2010 07:34
AstraZeneca has signed a deal with Teva Pharmaceuticals USA to settle patent litigation regarding Teva's proposed generic version of Astra's Entocort EC (budesonide) capsules used to treat Crohn's disease. The Anglo-Swedish drug giant has granted Teva a license to enter the US market with its gener
Read moreLondon close: Miners lead Footsie slide
4th May 2010 16:37
Footsie ended the day deep in the red after a poor start on Wall Street added to already heavy losses in London. The mining sector bore the brunt of the selling. BHP Billiton and Xstrata were initially among the worst fallers after they reacted angrily to the Australian government's plans to introd
Read moreLondon afternoon: Inmarsat bid spec a bright spot
4th May 2010 14:07
Footsie carried on falling over the lunch time session with sentiment taking a further knock from expectations of a lower start on Wall Street. BP is down heavily as the oil leak in the Gulf of Mexico shows no sign of abating. It has denied responsibility for the rig explosion that caused the prob
Read moreFDA green lights Astra's arthritis pill
4th May 2010 07:50
Anglo-Swedish drugs giant AstraZeneca said the US Food and Drug Administration (FDA) has approved VIMOVO, the pain relief pill for arthritis sufferers. VIMOVO, which was co-developed by Pozen and Astra, is a fixed-dose combination of delayed-release enteric-coated naproxen, a pain-relieving non-ste
Read moreFriday tips round-up: BG, AstraZeneca, William Hill
30th Apr 2010 06:39
BG's impressive portfolio - particularly in the giant sub-salt fields off Brazil and in Australia's coal-seam gas sector - should give investors pause for thought, regardless of the short-term dynamic. Australian LNG trains are well-placed for the booming Asian market. And Brazil's Santos Basin ha
Read moreLondon afternoon: BP left behind
29th Apr 2010 15:07
Footsie is trading close to its high for the day despite heavily weighted index constituent BP coming under the cosh after it said the oil leak in the Gulf of Mexico is much worse than initially thought. BP's chief operating officer Doug Suttles has admitted that the amount of oil leaking from the
Read more